The pharmaceutical company on Friday (26 August 2022) announced that its wholly owned subsidiary, Jubilant Draximage Inc. has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US drug regulator.
Jubilant Pharmova's subsidiary received EIR from the United States Food and Drug Administration (USFDA) for its radiopharmaceuticals manufacturing facility at Montreal Canada in respect of the inspection conducted by the regulatory agency from 6 June 2022 to 10 June 2022.
With the receipt of the EIR, the inspection stands successfully closed, the company stated.
Jubilant Pharmova is a global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, contract research and development services and proprietary novel drugs.
The company's consolidated net profit slumped 70.7% to Rs 47.04 crore on 10.7% drop in net sales to Rs 1,440.47 crore in Q1 FY23 over Q1 FY22.
Shares of Jubilant Pharmova were down 0.25% to settle at Rs 336.90 on Friday, 26 August 2022.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app